Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.[ADDRESS_140809] 
interaction study to evaluate the pharmacokinetics of doravirine and tenofovir disoproxil 
fumarate on the pharmacokinetics of cross -sex hormonal therapy in adult HIV -negative 
transgender women   
 
JeffTrial Protocol Number: [ZIP_CODE]  
[COMPANY_006] MISP Number: [ZIP_CODE]  
 
Principal Investigator: 
   
   
 [INVESTIGATOR_125264] K. Kraft, MD  
 
Department of Pharmacology & Experimental Therapeutics  
[ADDRESS_140810], 1170 Main Building  
Philadelphia, PA [ZIP_CODE]  
215 -955-6086  
 
Co-Investigator:  Edwin Lam, PharmD  
 
Department of Pharmacology & Experimental Therapeutics  
[ADDRESS_140811], 1 170 Main Building  
Philadelphia, PA [ZIP_CODE]  
[PHONE_2824]  
 
Study Site:  
 Thomas Jefferson University  
Funder:  
 [COMPANY_006] & Co., Inc.  
Study Compounds:  Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 
(DELSTRIGO ) 
Estradiol  
Spi[INVESTIGATOR_125265]:  
 1 
Protocol Date:  27 December 2021  
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.135   
Page 2 of 47 
  
PROTOCOL AMENDMENTS AND SUMMARY OF CHANGES  
 
Document  Version Date  Summary of Changes  
1.0 24 JANUARY 2020  Original IRB submission  
1.1 14 FEBUARY 2020  Revision s based on IRB 
review  
2.0            27 December 2021                     Update exclusion criteria, 
minor typographical 
corrections  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.[ADDRESS_140812] OF ABBREVIATIONS  ................................ ................................ ................................ ...............................  7 
PROTOCOL SUMMARY  ................................ ................................ ................................ ................................ .. 8 
SCHEDULE OF EVENTS  ................................ ................................ ................................ ................................ . 12 
1 INTRODUCTION  ................................ ................................ ................................ ................................ ... 15 
1.1 Study Background  ................................ ................................ ................................ .............................  15 
1.1.1 Transgender Women and Human Immunodeficiency Virus  ................................ ......................  15 
1.1.2 Gender Affirming Feminizing Hormone Therapy  ................................ ................................ .......  15 
1.1.3 Management of Human Immunodeficiency Virus Infection in Transgender Women ...............  15 
1.1.4 Overview of Doravirine/Lamivudine/Tenofovir disoproxil fumarate (DOR/3TC/TDF)  ..............  16 
1.1.5 Mechanism of Interaction  ................................ ................................ ................................ ..........  16 
1.1.6 Overview of Gender Affirming Feminizing Hormone Therapy  ................................ ..................  17 
1.2 Study Population and Dosing Rationale  ................................ ................................ ............................  17 
1.2.1 Rationale for Study Population  ................................ ................................ ................................ .. 17 
1.2.2 Rationale for Dose Selection  ................................ ................................ ................................ ...... 17 
1.3 Rationale for Endpoints  ................................ ................................ ................................ ....................  17 
1.3.1 Pharmacokinetic/Pharmacodynamic Endpoints  ................................ ................................ ........  17 
1.3.2 Safety Endpoints  ................................ ................................ ................................ ........................  18 
2 STUDY OBJECTIVES AND ENDPOINTS ................................ ................................ ................................ .. 18 
2.1 Objectives ................................ ................................ ................................ ................................ ..........  18 
2.1.1 Primary Objectives  ................................ ................................ ................................ .....................  18 
2.1.2 Secondary Objective  ................................ ................................ ................................ ..................  18 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.135   
Page 4 of 47 
 2.1.3 Exploratory Objective ................................ ................................ ................................ .................  18 
2.2 Endpoints  ................................ ................................ ................................ ................................ ..........  18 
2.2.1 Primary Endpoint  ................................ ................................ ................................ .......................  18 
3 STUDY DESIGN ................................ ................................ ................................ ................................ ..... 19 
4 PARTICIPANT SELE CTION  ................................ ................................ ................................ ....................  19 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...............................  19 
4.2 Exclusion Criteria  ................................ ................................ ................................ ...............................  20 
4.3 Study Drug and Adherence  ................................ ................................ ................................ ...............  20 
4.4 Participant Discontinuation and Withdrawal  ................................ ................................ ...................  21 
4.4 Participant Replacement Strategy  ................................ ................................ ................................ .... 21 
5 STUDY INTERVENTIONS  ................................ ................................ ................................ ......................  21 
5.1 Treatment Drugs  ................................ ................................ ................................ ...............................  21 
5.2 Treatment Allocation  ................................ ................................ ................................ ........................  22 
6 STUDY PROCEDURES  ................................ ................................ ................................ ...........................  22 
6.1 Overview  ................................ ................................ ................................ ................................ ...........  22 
6.2 Informed Consent  ................................ ................................ ................................ .............................  22 
6.2 Participant Recruitment and Screening  ................................ ................................ ............................  22 
6.3 Study Visit Schedule  ................................ ................................ ................................ ..........................  23 
6.3.1 Treatment A (Sequence E, Period I): Administration of DOR/3TC/TDF Alone  ...........................  23 
6.3.2 Treatment A (Sequence F, Period III): Administration  of DOR/3TC/TDF Alone  .........................  24 
6.3.3 Treatment B (Sequence E & F, Period II): Administration of Estradiol & Spi[INVESTIGATOR_8407]  .........  25 
6.3.1 Treatment C (Sequence F, Period I): Administration of DOR/3TC/TDF + 
Estradiol/Spi[INVESTIGATOR_8407]  ................................ ................................ ................................ ....................  26 
6.3.1 Treatment C (Sequence E, Period III): Administration of DOR/3TC/TDF + 
Estradiol/Spi[INVESTIGATOR_8407]  ................................ ................................ ................................ ....................  28 
6.4 Domiciling  ................................ ................................ ................................ ................................ .........  29 
6.5 Clinical Procedures & Assessments  ................................ ................................ ................................ ... 29 
6.5.1 Medical History  ................................ ................................ ................................ ..........................  29 
6.5.2 Physical Examination ................................ ................................ ................................ ..................  29 
6.5.3 12-Lead Electrocardiogram  ................................ ................................ ................................ ........  29 
6.5.4 Vital Signs  ................................ ................................ ................................ ................................ ... 29 
6.5.5 Laboratory Safety Evaluations  ................................ ................................ ................................ ... 30 
6.5.6 Prior and Concomitant Medications Review  ................................ ................................ .............  30 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.[ADDRESS_140813]  ................................ ................................ ................................ ..........  30 
6.8 Standardized Meals  ................................ ................................ ................................ ...........................  31 
6.9 Study, Drug Dosing, and Procedure Modification Permitted  ................................ ...........................  31 
6.10 Study Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ ......................  31 
7 POTENTIAL RISKS AND BENEFITS  ................................ ................................ ................................ ........  31 
7.1 Potential Risks Associated with Doravirine  ................................ ................................ .......................  31 
7.1 Potential Risks Associated with Lamivudine  ................................ ................................ .....................  32 
7.3 Potential Risks Associated with Tenofovir Disoproxil Fumarate  ................................ ......................  34 
10 SAFETY, ADVERSE EVENTS (AE) & SERIOUS  ADVERSE EVENTS (SAE)  ................................ ..................  35 
10.1 Definitions  ................................ ................................ ................................ ................................ .......  35 
10.1.1 Adverse Event (AE)  ................................ ................................ ................................ ...................  35 
10.1.2 Serious Adverse Event (SAE)  ................................ ................................ ................................ .... 36 
10.2 Assessing and Recording AEs & SAEs  ................................ ................................ ..............................  [ADDRESS_140814] Review  ................................ ................................ ................................ . 39 
12.2 Informed Consent  ................................ ................................ ................................ ...........................  39 
12.3 Participant Confidentiality  ................................ ................................ ................................ ..............  39 
13 SUPPORTING DOCUMENTATION  ................................ ................................ ................................ ........  40 
13.1 Appendix 1: Clinical Laboratory Tests  ................................ ................................ .............................  40 
13.2 Appendix 2: Adverse Events: Definitions and procedures fo r Recording, Evaluating, Follow -up and 
Reporting  ................................ ................................ ................................ ................................ ................  42 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.[ADDRESS_140815] OF TABLES  
 
Table 1:  Dose, frequency, route of administration, and protocol regimen under 
investigation………………………………………………………………………………………………....  21 
 
Table 2:  Published within -participant  standard deviations pharmacokinetic 
parameters and corresponding number of participants  to reject the null 
hypothesis with 80% 
power…………………………………………………………………………………………………………....  31 
 
Table 3:  Protocol required laboratory assessments .……………………………...………………………....  [ADDRESS_140816] OF FIGURES  
Figure 1:  Study flow for 12 participants..……………………….................................................  11 
 
 
 
 
 
 
 
 
 
 
 
 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.[ADDRESS_140817] sampled dose  
CBC Complete Blood Count  
CI Confidence interval  
Cmax Maximum concentration observed  
CMP  Complete Metabolic Panel  
CRU  Clinical Research Unit at Thomas Jefferson University  
Ctrough  Trough concentration  
CYP Cytochrome P450  
DDI Drug -Drug Interaction  
DOR  Doravirine  
ECG Electrocardiogram  
FDA  US Food and Drug Administration  
HIV Human Immunodeficiency Virus  
ICF Informed Consent Form  
IND Investigational New Drug  
mg Milligram  
NNRTI  Non -Nucleoside Reverse Transcriptase Inhibitor  
PK Pharmacokinetics  
PrEP  Pre-exposure prophylaxis  
QD Once Daily  
SAE Serious adverse event  
SS Steady State  
TGW  Transgender woman  
Tmax Time of maximum observable plasma concentration  
UA Urinalysis  
 
 
 
 
 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.135   
Page 8 of 47 
  
PROTOCOL SUMMARY  
 
Synopsis  
Transgender women (TGW) living with Human Immunodeficiency Virus (HIV) may prioritize 
gender -affirming hormonal therapy over antiretroviral (ARV) drug therapy. Hormonal therapy 
consists of oral estradiol and spi[INVESTIGATOR_8407], which induce drug -metabolizing e nzymes after 
prolonged administration. There is limited evidence evaluating the use of hormonal therapy 
together with HIV ARVs in TGW. TGW living with HIV may prioritize their gender -affirming 
therapy over ARVs. Doravirine/lamivudine/tenofovir disoproxil f umarate (DOR/3TC/TDF) is an 
ARV approved for the treatment of HIV -1 infection. DOR is primarily metabolized by 
[CONTACT_9058] P450 (CYP) 3A with 3TC and TDF having minimal CYP -mediated interactions. A 
drug interaction study is warranted in light of the 1) indu ctive effects of hormones on drug 
metabolizing enzymes, 2) common clearance pathway of DOR/3TC/TDF, and 3) need to 
understand this interaction in order to enhance the uptake of ARV treatment in TGW living 
with HIV. This study is designed to evaluate the bi -directional pharmacokinetic interaction 
between single -dose DOR/TDF in the presence of estradiol in TGW.  
Overview of Study Design  
Randomized, placebo -controlled, three -period crossover, two -way interaction study to 
evaluate the effect of once -daily DOR /TDF with estradiol/spi[INVESTIGATOR_125266] -negative 
transgender women. Participants will be randomized into two sequences and undergo period 
specific treatment options. For participants randomized to sequence A, participants will 
receive DOR/3TC/TDF alone ( Period I), placebo and hormone therapy (Period II), and 
DOR/3TC/TDF and hormone therapy (Period III). In sequence B, participants will receive 
DOR/3TC/TDF and hormone therapy (Period I), placebo and hormone therapy (Period II), and 
DOR/3TC/TDF alone (Perio d 3). There will be a 14 -day washout in between periods  I and II and 
II and III .   
Hypothesis  
The mean ratios for estradiol and doravirine /tenofovir disoproxil  fumarate (in both 
directions) will fall below or above the no -effect boundaries defined as 80 -125%, 
respectively.  
Objectives and Endpoints  
Primary Objectives  Primary Endpoint  
 Compare the change in plasma exposure -
time profile, defined as AUC (0-last), Cmax, and 
Ctrough , following a single oral dose of 
DOR/TDF together with 
estradiol/spi[INVESTIGATOR_125267] (0-last), Cmax, and C trough . 
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.135   
Page 9 of 47 
  Compare the change in plasma exposure -
time profile, defined as AUC (0-last), Cmax, and 
Ctrough , following a single oral dose of 
estradiol together with DOR/TDF  
Secondary Objective  Secondary Endpoint  
Evaluate the safety and tolerability of 
DOR/3TC/TDF when co -administered with 
estradiol and spi[INVESTIGATOR_125268] -emergent adverse events for 
safety parameters  
 
Exploratory Objective  Exploratory Endpoint  
Evaluate the change in baseline testosterone 
during the treatment periods  Change in plasma testosterone following 
treatment  
Study Population (Inclusion)  
1.  Healthy self -identified transgender women (male -to-female) between [ADDRESS_140818] not undergone an orchiectomy  
3. Receiving oral estradiol and spi[INVESTIGATOR_125269] > 3 months prior to study entry with a 
self-reported adherence to prescribed doses of > 90%  
4. Abstain from alcohol consumption throughout the duration of the study  
5. Be willing to briefly interrupt hormonal therapy prior to and during the study  
6. If on pre -expos ure prophylaxis (PrEP) therapy containing tenofovir alafenamide or 
disoproxil fumarate, willing to discontinue PrEP at least 2 weeks before study start 
and for the duration of the study   
7. Agree to use condoms for all sexual activity prior to the start and throughout the 
duration of the study  
8. Evidence of a personal signed and dated informed consent document indicating that 
the participant has been informed of all pertinent aspects of the study  
Study Population (Exclusion)  
1. Presence of clinically significant acute or chronic disease, that in the investigator’s 
opi[INVESTIGATOR_1649], would compromise the participant’s safety during the study  
2. Current use of any antiretroviral drug. This will not be exclusionary if participants 
reported disc ontinuing within 30 days of screening  
3. Creatinine clearance < 60 mL/min, as estimated by [CONTACT_16424] -Gault equation  
4. Known anaphylactic or severe systemic reactions to any components of doravirine, 
lamivudine, or tenofovir  
5. Positive HIV, Hepatitis B or Hep atitis C virus at screening. Evidence of prior Hepatitis B 
infection and immunity is not exclusionary. Positive hepatitis C antibody with negative 
viral load or documented antiviral hepatitis C treatment with one post treatment non -
detectable hepatitis C v iral load is not exclusionary  
6. Recent significant blood or plasma donation  
Investigating Drug interactions between antiretrovirals  and feminizing hormones (IDentify)  
Protocol Version: 2.0 
Protocol Date:   27 December 2021  
JeffTrial Number: [ZIP_CODE] – IRB #20C.[ADDRESS_140819] significant drug -
drug interactions  
8. Received study drug in another study within 4 weeks or within 5 half -lives; which ever 
occurring first - before first anticipated dose of study drug in this study  
9. Unable to refrain from use of over -the-counter, prescription (unless determined 
appropriate by [CONTACT_093]), herbal or natural products, vitamins or supplements, 
or grape fruit juice/grapefruit products  
10. Presents any concern by [CONTACT_125282] n and Doses  
Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo)  
Class: Antiretroviral  
Availability: 100 mg/300 mg/ 300 mg oral tablet  
Investigational dosing: 100 mg/300 mg/ 300 mg once -daily  
 
Estradiol (Various)  
Class: Feminizing Hormone  
Availability: Tablet  
Investigational dosing: 8 mg/day  
 
Spi[INVESTIGATOR_8407] (Various)  
Class: Anti -androgen  
Availability: Tablet  
Investigational dosing: 400 mg/day  
 
Number of Participants  
12 
 
 
 
 
 
 
 
 
 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 11 of 47 
 Figure 1. Study flow for 12 participants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 12 of 47 
 SCHEDULE OF EVENTS  
Treatment A  (DOR/3TC/TDF) – Sequence E (Period I); Sequence F  (Period III)   
 
 
Procedures  Days   
Post -
Study (7 -
14 days)  Screening 
(-30) Pre-
study 
(-14) Day 
-1 1 2 3 4 5 
Pre-
dose  PK Sampling (Hours)  
0 0.5 1 2 6 12 24 48 72 96 
Assessment of Eligibility  X               
Signed Consent Form  X               
Medical History  X  X             
Concomitant Medication Review  X X X X X      X X X X X 
Randomization    X1             Clinical 
Laboratory  Complete Blood Count  X  X            X 
Comprehensive Metabolic 
Panel  X  X            X 
HIV, Hepatitis B & C  X               
Alcohol & Drug Screen  X  X3             
Urinalysis  X  X             Clinical 
Procedure  
Physical Exam  X  X            X 
Vital Signs  X  X X       X    X 
Electrocardiogram  X               Research 
Labs  DOR/TDF PK     X  X X X X X X X X X  
Estradiol PK  X  X             
Total Testosterone  X   X  X X X X  X X  X  
Treatment  DOR/3TC/TDF      X           
SOC Hormone Therapy 
Interruption   X X             
Assessment of Adverse Events   X X X X X X X X X X X X X X 
Inpatient    X2 X ---------------------------------------------------------- ------- -X DC     
1Subjects will be randomized prior to any dosing  (for period 1)  after all eligibility criteria, including  day -1 procedures are met . 
2Participants  will admitted to the CRU the morning  of Day -1 for period I  and the afternoon for period III.  3Urine drug screen only  
 Abbreviations : DC = Discharge; DOR = Doravirine ; HIV = Human Immunodeficiency Virus; PK = Pharmacokinetics; SOC = Standard of care; TDF = Tenofovir Disoproxil Fumarate; 3TC  = Lamivudine  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 13 of 47 
 1Levels  will be taken  prior to the second estradiol dose . 
2Pre-dose Physical Exam may be done up to 24 hours prior to dose.  
3Participants will admitted to the CRU the afternoon of Day -1 on period II     4 Urine drug screen only  
Abbreviations: DC = Discharge; DOR = Doravirine; HIV = Human Immunodeficien cy Virus; PK = Pharmacokinetics ; SOC = Standard of care; TDF = Tenofovir Disoproxil Fumarate; 3TC = Lamivudine  
 Treatment B (Hormone therapy + Placebo) – Sequence E & F  (Period II)  
 
 
Procedures  Days  
Screening   
(-30) Pre-
study   
(-14) 1 2 3 4 5 
Day         
-1 Pre-
dose  PK Sampling (Hours)  
0 0.5 1 2 6 12 24 48 72 96 
Assessment of Eligibility  X              
Signed Consent Form  X              
Medical History  X  X            
Concomitant Medication 
Review  X X X X           Clinical Laboratory  Complete Blood 
Count  X  X            
Comprehensive 
Metabolic Panel  X  X            
HIV, Hepatitis B & C  X              
Alcohol & Drug 
Screen  X  X4            
Urinalysis  X  X            Clinical 
Procedures  Physical Exam  X  X2            
Vital Signs  X  X X       X    
Electrocardiogram  X              Research 
Labs  Estradiol PK  X  X X1  X  X X X X X X X 
Total Testosterone  X   X1  X X X X  X X  X Treatment  Placebo  for 
DOR/3TC/TDF      X          
SOC Hormone 
Therapy Restart    X  X          
SOC Hormone 
Therapy Interruption   X             
Assessment of Adverse Events   X X X X X X X X X X X X X 
Inpatient    X X3        ---------------------------------------------------------- ------- -X DC    
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 14 of 47 
  
Treatment C  (DOR/3TC/TDF + Hormone Therapy)  – Sequence E (Period III); Sequence F  (Period I)   
 
 
Procedures  Days   
Post-Study 
(7-14 days)  
Screening 
(-30) Pre-
study 
(-14) 1 2 3 4 5  
Day -1 Pre-
dose  PK Sampling (Hours)   
0 0.5 1 2 6 12 24 48 72 96  
Assessment of Eligibility  X               
Signed Consent Form  X               
Medical History  X  X             
Concomitant Medication Review  X X X X           X 
Randomization    X             Clinical Laboratory  Complete Blood Count  X  X            X 
Comprehensive 
Metabolic Panel  X  X            X 
HIV, Hepatitis B & C  X               
Alcohol & Drug Screen  X  X4             
Urinalysis  X  X             Clinical 
Procedure
s Physical Exam  X  X            X 
Vital Signs  X  X X       X    X 
Electrocardiogram  X               Research Labs  
DOR/TDF PK      X X X X X X X X X X  
Estradiol PK  X  X X2  X  X X X X X X X  
Total Testosterone  X   X2  X X X X  X X  X  
Treat
ment  DOR/3TC/TDF      X           
SOC Hormone Therapy 
Restart    X  X           
SOC Hormone Therapy 
Interruption   X              
Assessment of Adverse Events   X X X X X X X X X X X X X X 
Inpatient    X3 X   ---------------------------------------------------------- ------- -X DC     
1Subjects will be randomized prior to any dosing (for period 1) after all eligibility criteria, including  day -1 procedures are met . only 2Levels  will be taken prior to the second estradiol dose.  
3Participants  will admitted to the CRU the morning  of Day -1 for period I and  the afternoon for period III  4 Urine drug screen. Abbreviations: DC = Discharge; DOR = Doravirine ; HIV = Human 
Immunodeficiency Virus; PK = Pharmacokinetics; SOC = Standard of care; TDF = Tenofovir Disoproxil Fumarate; 3TC = Lamivudine
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 15 of 47 
 1 INTRODUCTION  
1.1 Study Background  
1.1.1  Transgender Women and Human Immunodeficiency Virus  
It is estimated that 1 million people identify as transgender (both male -to female and female -to-
male) in the [LOCATION_002].1 Transgender is a term for people whose gender identity differs from 
what is associated with their sex assigned at birth. A transgender woman (TGW) refers to a person 
who wa s assigned male at birth but identifies and lives as a woman.2 The global prevalence of 
Human Immunodeficiency Virus (HIV) infection is  estimated to be 19% among TGW.3 
Transgender women represent approximately 22 -28% of the 1.1 million adults living with HIV in 
the [LOCATION_002] with a new diagnosis 3 times the n ational average.1 TGW are disproportionally 
affected, as they are 49 times more likely to be infected with  HIV compared to the general 
population.3 Furthermor e, HIV infections are more prevalent in TGW compared to transgender 
men (21% vs. 1.2%, respectively) with approximately 70% of TGW  with HIV  being Black or 
Hispanic.1,4,[ADDRESS_140820] issued guidance on 
initiating  and monitoring feminizing hormone therapy. Common hormone regimens in TGW 
include estrogens, antiandrogens, and progesterone. 17 -estradiol is the bioidentical hormone 
produced in the ovary and is the most common estrogen used in feminizing therapy. Oral,  
transdermal, and parenter al routes of administration for 17-estradiol are available. 
Spi[INVESTIGATOR_74963] 5 -alpha reductase inhibitors are among the common oral antiandrogens used 
to block the effects of testosterone or suppress its production, respective ly. Serum estradiol and 
testosterone are used to monitor therapy with recommendations to maintain physiological levels 
between 100 -200 pg/mL and <50 ng/dL, respectively.2 It is estimated that 70% of TGW use non -
injection hormones with 33% who use injectable hor mone therapy in the [LOCATION_002].    
1.1.3 Management of Human Immunodeficiency Virus Infection in Transgender Women   
Antiretroviral (ARV) therapy is recommended to individuals infected with HIV to prevent 
progression to immunodeficiency, premature death , and transmission. Initial therapy generally 
consists of two nucleoside reverse transcriptase inhibitors (NRTI) in combination with other ARV 
classes such as integrase strand transfer inhibitor, protease inhibitors or non -nucleoside reverse 
transcriptase inhibitors (NNRTIs).[ADDRESS_140821] 
frequently use tenofovir (79%) with 23% using abacavir.7 Twenty -eight percent reported using an 
NNRTI based regimen. NNRTIs, such as doravirine (DOR), may be an optimal choice for some TGW 
based on its low potential for drug -drug interaction (DDI), tolera bility , and availability as a  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 16 of 47 
 once -daily fixed -dose regimen together with lamivudine (3TC) and TDF. The favorable metabolic 
profile of DOR ma kes it favored in those with dyslipi[INVESTIGATOR_125270] , especially since  TGW are at a higher 
risk for cardiovascular events due to HIV infection and hormone  therapy.8-10    
 
A recent cross -sectional study by [CONTACT_125283]. has raised concerns over suboptimal ARV adherence 
in TGW living with HIV on feminizing hormone therapy.7 Of the half of study participants who 
were living with HIV, 57% were concerned with the DDI potential with 40% repor ting not using 
ARVs, hormone therapy, or both because of this concern.     
1.1.4  Overview of Doravirine/ Lamivudine/T enofovir disoproxil fumarate (DOR/3TC/TDF)  
Doravirine is a novel NNRTI approved for use in patients with HIV -1 in combination with 3TC 
and T DF. The pharmacokinetics of doravirine is expected to be similar between healthy 
volunteers and those living with HIV -1. DOR/3TC/TDF is a complete regimen for the treatment 
of HIV -[ADDRESS_140822] shown  that chronic elevated exposures of 17 -estradiol induce phase I and II drug 
metabolizing enzymes through enhancing major transcription factors that regulate the 
expression of drug metabolizing enzymes.11-13 Similarly, the metabolite 17 -estradiol 
glucuronide, has been shown to regulate multidrug resistance -associate protein 2 (MDR2) 
regulation, which was associated with changes in transporter activity in in -vitro  human 
intestinal cells.[ADDRESS_140823] study 
observed a 13% reduction in the TDF exposure with concurrent feminizing hormone therapy 
with no  change in hormone levels. The authors concluded that there were no significant 
interactions in both directions. However, the results of this study may not be generalizable to 
TGW in the US. First, due to its fixed -sequence design, the study was unable to estimate the 
within -participant variability in drug exposure or designed to test no -effect boundaries. Second, 
the inductive effects from high dose hormone therapy may not have been truly witnessed given 
that TGW enrolled were just beginning hormone therap y or had not received hormones within 
the past 6 months.  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 17 of 47 
 1.1.6  Overview of Gender Affirming Feminizing Hormone Therapy  
[IP_ADDRESS] 17 -Estradiol  
Oral 17- Estradiol (estradiol) is the most common hormone used for feminizing therapy. 
Estradiol is the bioidentical hormone to that of the human ovary. Titration upwards over 3 -6 
months together with laboratory monitoring for estradiol and testosterone levels over time is 
common practice.  
[IP_ADDRESS] Spi[INVESTIGATOR_125271]-androgens are used alongside estradiol to reduce masculinization and reduce testosterone 
levels. Spi[INVESTIGATOR_125272] -androgen in the [LOCATION_002]. 
Suppression of testosterone production minimizes and sup presses male secondary sexual 
characteristics and lowers estradiol dosing.  
1.2 Study Population and Dosing Rationale  
1.2.1 Rationale for Study Population  
Clinical research in the TGW population is limited. There is a high burden of HIV in TGW that is 
disproportional to cisgender men and women. In the [LOCATION_002], the rate of new diagnosis for 
HIV infection is 3 times greater than the national average. TGW are less likely to seek access to 
healthcare for the fear of stigma, insensitivity, and discrimina tion. Despi[INVESTIGATOR_125273] -
exposure prophylaxis (PrEP), concerns arise when it is co -administered with hormone therapy 
reducing uptake of PrEP among TGW. Moreover, those living with HIV are less likely to take ARVs 
or maintain adequate viral loa d suppression as TGW may prioritize hormone therapy first for fear 
that ARVs may compromise hormone therapy.  
1.2.2 Rationale for Dose Selection  
[IP_ADDRESS] DOR/3TC/TDF  
DOR/3TC/TDF 100 mg/300 mg/300 mg was selected based on the approved doses marketed in 
the [LOCATION_002].  
[IP_ADDRESS] 17 -Estradiol  
A maximum dose of 8mg/day oral estradiol was selected based on the Guidelines for the 
Primary and Gender -Affirming Care of Transgender and Gender Nonbinary People published by 
[CONTACT_125284].19 
[IP_ADDRESS] Spi[INVESTIGATOR_8407]  
A maximum dose of 400 mg/day oral spi[INVESTIGATOR_125274] -Affirming Care of Transgender and Gender Nonbinary People 
published by [CONTACT_125285] U niversity of [LOCATION_004].  
   
1.3 Rationale for Endpoints  
1.3.1 Pharmacokinetic/Pharmacodynamic Endpoints  
For estradiol, plasma estradiol concentrations were selected to estimate the PK parameters for 
estradiol exposure during feminizing hormone therapy. Se rial PK sampling will determine the 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 18 of 47 
 interaction potential between DOR/3TC/TDF over a period of one dosing interval for both 
drugs.  
 
For DOR/TDF, plasma DOR/TDF concentrations were selected  to estimate the PK parameters for 
DOR/3TC/TDF exposure when co -administered with hormone therapy. Serial PK sampling will  
determine the interaction potential between estradiol and DOR/TDF over a period of one 
dosing interval for both drugs.  
1.3.2 Safety  Endpoints  
The safety for DOR/3TC/TDF, estradiol, and spi[INVESTIGATOR_125275]. This study will 
observe the safety and tolerability following co -administration with feminizing hormone 
therapy in healthy transgender women. Given the extensive ex perience of these drugs, it is not 
expected that the current study will be sensitive to detect new or uncommon safety events 
associated with co -administration.  
2 STUDY OBJECTIVES AND ENDPOINTS  
2.1 Objectives  
2.1.1 Primary Objective s 
 Evaluate the plasma co ncentration -time profile, defined as AUC (0-last), AUC (0-inf), and  Cmax 
of estradiol when co -administered with doravirine/lamivudine/tenofovir disoproxil 
fumarate.  
 Evaluate the plasma concentration -time profile, defined as AUC (0-last), AUC (0-inf), and C max , 
of doravirine and tenofovir disoproxil fumarate when co -administered with estradiol 
and spi[INVESTIGATOR_8407].  
2.1.2 Secondary Objective  
 Evaluate the safety and tolerability of doravirine /lamivudine/tenofovir disoproxil 
fumarate  when co -administered with estrad iol and spi[INVESTIGATOR_125276].  
2.1.3 Exploratory Objective  
 Evaluate the change in plasma testosterone when doravirine/lamivudine/tenofovir 
disoproxil fumarate is co -administered with estradiol.  
2.2 Endpoints  
2.2.1 Primary Endpoint  
 Change in the estradiol plasma concentration -time profile, as defined by [CONTACT_12265] (0-last), 
AUC (0-inf), and  Cmax 
 Change in the doravirine and tenofovir disoproxil fumarate plasma concentration -time 
profile, as defined by [CONTACT_12265] (0-last), AUC (0-inf), and  Cmax 
 
2.2.2 Second ary Endpoint   
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 19 of 47 
 Proportion of Participants  experiencing adverse event(s) characterized by [CONTACT_24975], 
frequency, severity, timing and laboratory abnormalities - and tolerability of the co -
administered drugs.  
 
2.2.1 Exploratory Endpoint   
Change in plasma testosterone following doravirine/lamivudine/tenofovir disoproxil 
fumarate administration   
[ADDRESS_140824] between 
doravirine/lamudine/tenofovir disoproxil fumarate and cross -sex hormones.  
 
Twelve healthy HIV -negative adult participants  who identify as a transgender woman will be 
enrolled.  
 
Participants will be randomized into two  sequences (6 participants per sequence). Participants 
will undergo treatment specific groups for each period with a 14 -day washout in between 
periods I and II  and II and III . In treatment A, a single dose of DOR/3TC/TDF 100 mg/300 mg/[ADDRESS_140825] -of-care hormone 
regimens together with placebo in treatment B. Lastly, Treatment C will be co -administration of 
DOR/3TC/TDF 100 mg/300 mg/[ADDRESS_140826] -of-care hormone therapy. Figure  
1 displays the study schematic.  
4 PARTICIPANT SELECTION  
4.1 Inclusion Criteria  
Participant  eligibility should be reviewed and documented by [CONTACT_4653]’s study team before patients are included in the study.  
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
study:  
1. Healthy self -identified transgender women (male -to-female) between [ADDRESS_140827] not undergone an orchiectomy  
3. Receiv ing oral estradiol and spi[INVESTIGATOR_125269] > 3 months prior to study entry with a 
self-reported adherence to prescribed doses of > 90%  
4. Abstain from alcohol consumption throughout the duration of the study  
5. Be willing to briefly interrupt hormonal therapy pr ior to and during the study  
6. If on pre -exposure prophylaxis (PrEP) therapy containing tenofovir alafenamide or 
disoproxil fumarate, willing to discontinue PrEP at least 2 weeks before study start and 
for the duration of the study   
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 20 of 47 
 7. Agree to use condoms for all sexual activity prior to the start and throughout the 
duration of the study  
8. Evidence of a personal signed and dated informed consent document indicating that the 
participant has been informed of all pertinent aspects of the study  
 
4.2 Exclusion Criter ia 
Participants  with any of the following characteristics or conditions will not be included in the 
study:  
1. Presence of clinically significant acute or chronic disease, that in the investigator’s 
opi[INVESTIGATOR_1649], would compromise the participant’s safety during th e study  
2. Current use of any antiretroviral drug. This will not be exclusionary if participants 
reported discontinuing within 30 days of screening  
3. Creatinine clearance < 60 mL/min, as estimated by [CONTACT_16424] -Gault equation  
4. Known anaphylactic or severe systemic reactions to any components of doravirine, 
lamivudine, or tenofovir disoproxil fumarate  
5. Positive HIV, Hepatitis B or Hepatitis C virus at screening. Evidence of prior Hepatitis B 
infection and immunity is not exclusion ary. Positive hepatitis C antibody with negative 
viral load or documented antiviral hepatitis C treatment with one post treatment non -
detectable hepatitis C viral load is not exclusionary  
6. Recent significant blood or plasma donation  
7. Concomitant use of drugs, as deemed by [CONTACT_093], to have significant drug -drug 
interactions  
8. Received study drug in another study within 4 weeks or within 5 half -lives; whichever 
occurring first - before first anticipated dose of study drug in this study  
9. Unable to ref rain from use of over -the-counter, prescription (unless determined 
appropriate by [CONTACT_093]), herbal or natural products, vitamins or supplements, or 
grapefruit juice/grapefruit products  
10. Presents any concern by [CONTACT_125286]  
4.[ADDRESS_140828] be willing and able to adhere to the following lifestyle restricti ons 
during the course of the study in order to be eligible for participation:  
1. If drinks alcohol, participant should have < 3 drinks per day   
2. With the exception of marijuana,  illicit drugs , should be avoided t hroughout the study 
duration  
3. Use of prescriptio n or non -prescription drugs, including vitamins, herbal and dietary 
supplements, unless at the opi[INVESTIGATOR_871], not compromise the safety of the 
participant   
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 21 of 47 
 4.4 Participant Discontinuation and Withdrawal  
Participants may withdraw consent at a ny time for any reason. In addition, a participant may be 
withdrawn by [CONTACT_125287], the trial plan is 
violated, or for administrative and/or other safety reasons. Participants who miss any 
treatment dose w ill be discontinued from the study. Any participant who suffers a serious 
safety adverse events possibly - or probably -related -to study intervention will be discontinued. 
If more than three participants  are discontinued due to possibly - or probably -related -to study 
intervention, the study will be terminated . 
4.4 Participant Replacement Strategy   
If a participant discontinues from the trial, a replacement participant may be enrolled if 
deemed appropriate by [CONTACT_473]. The replacement parti cipant will  undergo the same 
treatment sequence (as appropriate) as the participant being replaced  beginning at period I 
through period III.   
[ADDRESS_140829], doravirine/lamivudine/tenofovir disoproxil  fumarate, will be 
used in this study. Participants will be using their standard of care hormone therapy consisting 
of estradiol and spi[INVESTIGATOR_8407].  
 
Table 1  highlights the dose, frequency, route of administration, and protocol regimen under 
investigation.  
 
Table 1 : Dose, frequency, route of administration, and protocol regimen under investigation  
Drug  Maximum 
Dose 
during 
the study  Dosage 
Form  Dosing 
Frequency  Route of 
Administration  Protocol Regimen  
Doravirine/  
Lamivudine/  
Tenofovir 
disoproxil 
fumarate  100 mg/       
300 mg/       
300 mg  Tablet  Once -daily 
for one 
dose  Oral  One time dose for  
treatment groups 
A & C  
Estradiol  8 mg  Tablet  4 mg twice -
daily for 
two doses  Oral  One time dose for 
treatment group B 
& C 
Spi[INVESTIGATOR_8407]  400 mg  Tablet  200 mg 
twice -daily 
for two 
doses  Oral  One time dose for 
treatment group B 
& C 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 22 of 47 
 Placebo  NA Tablet  Once -daily 
for one 
dose  Oral  One time dose for 
treatment group B  
 
5.2 Treatment Allocation  
Participants will be screened using a screening number (SN) consisting of an alpha -numeric 
code starting with SN 1001. Allocation numbers will begin with 201. Replacement Participants  
will begin with allocation 301.  
6 STUDY PROCEDURES  
6.1 Overview  
Procedures to be performed at each visit are summarized on the table of scheduled events. It 
may be necessary to perform study procedures at unscheduled time points if deemed clinically 
necessary by [CONTACT_093]. Additional evaluations/te sting may be deemed necessary by [CONTACT_125288].  
Trial procedures should be completed as close to the prescribed/scheduled time as possible.  
Any nonscheduled procedures required for urgent evaluat ion of safety concerns take 
precedence over all routine scheduled procedures.  
6.[ADDRESS_140830] be documented by [CONTACT_2299]’s dated signature [INVESTIGATOR_2394] a consent form along 
with the dated signature [CONTACT_125298]. A copy of the signed 
and dated consent form will be given to the participant  before participation in the trial. The 
participant  will be informed in a timely manner if new information becomes available that may 
be relevant to the participant ’s willingness to continue participation in the trial.  The informed 
consent will adhere to institutional review board (IRB) requirements, applicable laws and 
regulations.  
6.[ADDRESS_140831] 8 hours prior to the screening visit labs being drawn. The following 
proc edures/assessments will be performed during the screening visit:  
 Medical history  
 Vital signs  
 Physical examination  
 Electrocardiogram (ECG)  
 Concomitant medication review  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 23 of 47 
  Laboratory safety tests including:  
o Complete blood count with differential and complet e metabolic panel  
 Hepatitis B surface antigen, Hepatitis C antibody and HIV tests  
 Estradiol and testosterone level  
 Urine drug screen  
 Urinalysis  
 Estradiol/testosterone level  
6.3 Study Visit Schedule  
In addition to the procedures and assessments detailed be low- adverse events and concomitant 
medication will be assessed. Any nonscheduled procedures required for urgent evaluation of safety 
concerns take precedence over all routine scheduled procedures.  
6.3.1 Treatment A (Sequence E, Period I): Administration of DOR/3TC/TDF Alone  
 Study Day -14 
Participants will be scheduled to discontinue their hormone therapy -14 days before the initial 
study start date. Participants will be randomized 1:1 to either sequence E or F.  
 
 Study Day -1  
Participants will report to the CRU in the morning . The following procedures/ assessments  will be 
performed:  
- Urine drug screen  
- Lab Safeties  
- Urinalysis  
- Physical exam  
- Vital signs  
- Estradiol PK  
 
 Study Day 1  
Assessments:  Vital signs, adverse events, and concomitant medication review prior to dosing  
Pre-Dose PK:  A PK will be drawn prior to dosing of DOR/3TC/TDF (time 0 = pre -dose) ,  Physical 
exam (may be done up to 24 hours prior to dose)  
Pre-Dose Research Labs:  Total testosterone will be drawn prior to dosing DOR/3TC/TDF (time 0 
= pre -dose)  
Dosing:  Participants will be given only DOR/3TC/TDF (100mg/300mg/300mg) with [ADDRESS_140832] -Dose PK:  PK will be drawn 0.5, 1, 2, 6, and [ADDRESS_140833] -Dose Rese arch Labs:  Total testosterone will be drawn following DOR/3TC/TDF dose at 0.5, 
1, [ADDRESS_140834] study day 1 dose  
 
 Study Day 2  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140835] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140836] -dose PK  
 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 24 of 47 
  Study Day 3  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140837] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140838] study day 1 dose  
Participants will be discharged from the C RU following assessments and procedures  
 
 Study D ay 4 
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140839] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140840] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures  
 
 Study Day 5  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140841] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140842] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures and advised 
to not use hormone therapy for a washout period of 14 days  
 
6.3.2 Treatment A (Sequence F, Period I II): Administration of DOR/3TC/TDF Alone  
 Study Day -[ADDRESS_140843] a 14 day washout from Period II prior to entry into period III  
 
 Study Day -1  
Participants will report to the CRU in the evening. The following procedures/assessments will be 
performed:  
- Urine drug screen  
- Urinalysis  
- Physical exam  
- Vital signs  
- Estradiol PK  
 
 Study Day 1  
Assessments:  Vital signs, adverse events, and conco mitant medication review prior to dosing  
Pre-Dose PK:  A PK will be drawn prior to dosing of DOR/3TC/TDF (time 0 = pre -dose)  
Pre-Dose Research Labs:  Total testosterone will be drawn prior to dosing DOR/3TC/TDF (time 0 
= pre -dose)  
Dosing:  Participants will be given only DOR/3TC/TDF (100mg/300mg/300mg) with [ADDRESS_140844] -Dose PK:  PK will be drawn 0.5, 1, 2, 6, and [ADDRESS_140845] -Dose Research Labs:  Total testosterone will be drawn following DOR/3TC/TDF dose at 0.5, 
1, [ADDRESS_140846] study day 1 dose  
 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 25 of 47 
  Study Day 2  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140847] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140848] -dose PK  
 
 Study Day 3  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and con comitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140849] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140850] study day 1 dose  
Participants will be discharged from the CRU following assessments and proced ures  
 
 Study Day 4  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140851] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140852] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures and  advised 
to restart hormone therapy  
 
 Study Day 5  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant  medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140853] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140854] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures and  advised 
to restart hormone therapy  
 
6.3.3 Treatment B (Sequence E & F, Period II): Administration of Estradiol & Spi[INVESTIGATOR_8407]  
 Study Day -[ADDRESS_140855] a 14 day washout from Period I prior to entry of period II  
 
 Study Day -1  
Participants will report to the CRU in the evening. The following procedures/assessments will be 
performed  prior to dosing : 
- Urine drug screen  
- Urinalysis  
- Physical exam  
- Vital signs  
- Estradiol PK  
Dosing:  Participants will be given oral estradiol 4 mg and spi [INVESTIGATOR_8407] 200 mg with 8 ounces 
of water in the evening following performed procedure/assessments  
 
 Study Day 1  
Assessments:  Vital signs, adverse events, and concomitant medication review prior to dosing  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 26 of 47 
 Pre-Dose PK:  A PK will be drawn prior to dosing of estradiol and spi[INVESTIGATOR_8407] (time 0 = pre -
dose)  
Pre-Dose Research Labs:  Total testosterone and estradiol will be drawn prior to dosing estradiol 
and spi[INVESTIGATOR_8407]  (time 0 = pre -dose)  
Dosing:  Participants will be given placebo + estradiol [ADDRESS_140856] -Dose PK:  PK will be drawn at 2, 6, and [ADDRESS_140857] -Dose Research Labs: Total testosterone will be drawn following estradiol and 
spi[INVESTIGATOR_125277] 0.5, 1, 2, and [ADDRESS_140858] study  day 1 dose  
 
 Study Day 2  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140859] -dose Research Labs:  Total testosterone will be drawn [ADDRESS_140860] -dose PK  
 
 Study Day 3  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140861] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140862] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures  
 
 Study Day 4  
Participants will arrive in the morning to th e CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140863] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140864] study day 1 dose  
Participants will be discharged from  the CRU following assessments and procedures  
 
 Study Day 5  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK:  PK will be drawn [ADDRESS_140865] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140866] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures and advised 
to not use hormone therapy for a washout period of 14 days  
 
6.3.1 Treatment C (Sequence F , Period I): Administration of DOR/3TC/TDF + 
Estradiol/Spi[INVESTIGATOR_8407]  
 Study Day -14 
Participants will be scheduled to discontinue their hormone therapy -14 days before the initial 
study start date. Participants will be randomized 1:1 to either sequence E or F. 
 
 Study Day -1  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 27 of 47 
 Participants will report to the CRU in the evening. The following procedures/assessments will be 
performed:  
- Urine drug screen  
- Urinalysis  
- Physical exam  
- Vital signs  
- Estradiol PK  
Dosing: Participants will be given  oral estradiol 4 mg and spi[INVESTIGATOR_8407] 200 mg with 8 ounces 
of water in the evening following performed procedure/assessments  
 
 Study Day 1  
Assessments:  Vital signs, adverse events, and concomitant medication review prior to dosing  
Pre-Dose PK:  A PK will b e drawn prior to dosing of DOR/3TC/TDF  + estradiol and spi[INVESTIGATOR_8407]  
(time 0 = pre -dose)  
Pre-Dose Research Labs:  Total testosterone will be drawn prior to dosing DOR/3TC/TDF (time 0 
= pre -dose)  
Dosing:  Participants will be given only DOR/3TC/TDF (100mg/3 00mg/300mg) + estradiol [ADDRESS_140867] -Dose PK  (Estradiol) : PK wi ll be drawn 0.5, 1, 2, and [ADDRESS_140868] -Dose PK  (DOR/TDF) : PK will be drawn 0.5, 1, 2, 6, and [ADDRESS_140869] -Dose Research Labs:  Total testosterone will be drawn following DOR/3TC/TDF dose at 0.5, 
1, [ADDRESS_140870] study day 1 dose  
 
 Study Day 2  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140871] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140872] -dose PK  
 
 Study Day 3  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140873] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140874] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures  
 
 Study Day 4  
Participants will arrive in the morning to the CRU  
Asses sments:  Adverse events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140875] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140876] study day 1 dose  
Participants will be disc harged from the CRU following assessments and procedures and advised 
to not use hormone therapy for a washout period of 14 days  
 
 Study Day 5  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 28 of 47 
 Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140877] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140878] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures and advised 
to not use hormone therapy for a washout period of 14 days  
 
6.3.1 Treatment C (Sequence E, Period III): Administration of DOR/3TC/TDF + 
Estradiol/Spi[INVESTIGATOR_8407]  
 Study Day -[ADDRESS_140879] a 14 day washout from Period I prior to entr y of period II  
 
 Study Day -1  
Participants will report to the CRU in the evening. The following procedures/assessments will be 
performed:  
- Urine drug screen  
- Urinalysis  
- Physical exam  
- Vital signs  
- Estradiol PK  
Dosing: Participants will be given  oral estradiol 4 mg and spi[INVESTIGATOR_8407] 200 mg with 8 ounces 
of water in the evening following performed procedure/assessments  
 
 Study Day 1  
Assessments:  Vital signs, adverse events, and concomitant medication review prior to dosing  
Pre-Dose PK:  A PK will b e drawn prior to dosing of DOR/3TC/TDF  + estradiol and spi[INVESTIGATOR_8407]  
(time 0 = pre -dose)  
Pre-Dose Research Labs:  Total testosterone will be drawn prior to dosing DOR/3TC/TDF (time 0 
= pre -dose)  
Dosing:  Participants will be given  only DOR/3TC/TDF (100mg/300mg/300mg) + estradiol [ADDRESS_140880] -Dose PK  (Estradiol) : PK wi ll be drawn 0.5, 1, 2, and [ADDRESS_140881] -Dose PK (DOR/TDF) : PK will be drawn 0.5, 1, 2, 6, and [ADDRESS_140882] -Dose Research Labs:  Total testosterone will be drawn following DOR/3TC/TDF dose at 0.5, 
1, [ADDRESS_140883] study day 1 dose  
 
 Study Day 2  
Assessments:  Adverse events an d concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140884] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140885] -dose PK  
 
 Study Day 3  
Participants will arrive in the morning to the CRU  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 29 of 47 
 Assessments:  Adverse events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140886] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140887] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures  
 
 Study Day 4  
Participants will arrive in the morning to the CRU  
Assessments:  Adver se events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140888] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140889] study day 1 dose  
Participants will be discharged from t he CRU following assessments and procedures and advised 
to restart hormone therapy  
 
 Study Day 5  
Participants will arrive in the morning to the CRU  
Assessments:  Adverse events and concomitant medication review  
Post -Dose PK  (DOR/TDF + estradiol) : PK will be drawn [ADDRESS_140890] -Dose Research Labs:  Total testosterone will be drawn [ADDRESS_140891] study day 1 dose  
Participants will be discharged from the CRU following assessments and procedures and advised 
to restart hormone ther apy 
6.4 Domiciling  
Participants will be admitted to the CRU as outli ned in the schedule of events.  
6.5 Clinical Procedures & Assessments  
6.5.1 Medical History  
Medical history of Participants participating in the study will be obtained by [CONTACT_125289]-investigator(s).  
6.5.2 Physical Examination  
The full physical examination includes evaluation of the head, eye, ear, nose and throat; the 
cardiovascular, dermatological, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal and neurological 
systems. The screening examination will also include height and weight for BMI calculation.  
6.5.[ADDRESS_140892] 2 minutes prior to measurement of vital signs. 
Measurements include heart rate, blood pressure and respi[INVESTIGATOR_697]. Oral or tympanic 
temperature will be checked during the screening visit and if needed by [CONTACT_125290] -investigator, during and after the study.  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ADDRESS_140893] of clinical laboratory tests. Laboratory tests will be performed at 
screening, during and after the study.  
 The investigator or  medically qualified designee will review the laboratory report, 
document this review, and record any clinically relevant changes occurring during the 
study that meet the reporting requirements in the AE section of the CRF. The laboratory 
reports must be f illed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, 
unless judged by [CONTACT_19448]’s 
condition.   
 For an y laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_140894] < 3 drinks/day.    
6.6.[ADDRESS_140895] -study visit.  
6.6.4 Activity Restrictions  
Participants will avoid unaccustomed strenuous physical activity (i.e., wei ght lifting, running, 
bicycling, etc.) from the screening visit, throughout the trial until the post -trial visit. Participants 
may participate in light recreational activities during studies (eg, watching television, reading).  
6.[ADDRESS_140896] information  (including direct telephone 
numbers) to be utilized in the event of an emergency.  The investigator or qualified designee 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ADDRESS_140897] after  their  written informed 
consent.  
6.8 Standardized Meals  
Meal s (Breakfast, lunch, dinner and snacks) will be provided to participants during the 
admission days. Participants will be fasting for at least [ADDRESS_140898] dose for all study drugs.  
6.9 Study, Drug Dosing, and Procedure Modification Permitted  
Modifications to the dose, dosing regimen and clinical or laboratory procedures may be 
required to achieve the scientific goals of the trial objectives and/or to ensure appropriate 
safety monitoring of the study Participants.  As such, some alterations from the currently 
outlined schedule may be necessary. Additional laboratory safety tests may be drawn or added 
to blood samples previously drawn to obtain additiona l safety information (e.g., creatinine 
kinase to evaluate elevated AST/ALT). These changes may or may not increase the number of 
study procedures for a given  participant  during his/her participation in the entire study.    
6.[ADDRESS_140899] common adverse events (for All Grades) have been reported ( > 5%) with the 
chronic use of doravirine in patients with HIV infection. The reported adverse event rates 
reflect chronic daily use together with other ARVs and are derived from large clinical trials in 
patients with HIV. Although these adverse e vent rates have been reported in patients, it may be 
possible that healthy volunteers may also experience these side effects under this protocol.   
 Central nervous system:  
o Altered sensorium (Doravirine + 3TC + TDF: 4%)  
 Defined as: altered state of consciousness, lethargy, somnolence, 
syncope  
o Sleep disorders and disturbances (Doravirine + 3TC + TDF: 12%)  
 Defined as: abnormal dreams, hyposomnia, initial insomnia, insomnia, 
nightmare, sleep disorder, somnambulism  
o Dizzine ss (Doravirine + 3TC + TDF: 9%)  
o Fatigue (4 -6%) 
o Headache (4 -6%)   
 Gastrointestinal:   
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 32 of 47 
 o Nausea (5 -7%) 
o Diarrhea (3 -5%) 
 Laboratory abnormalities  
o Total bilirubin 1.1 - < 1.[ADDRESS_140900] (4 -5%)  
Less commonly reported ( < 2%) with chronic use of doravirine in patien ts with HIV on 
concomitant ARVs include:  
 Dermatologic  
o Rash (2%)  
 Laboratory abnormalities  
o Total bilirubin  
 1.6 - <2.[ADDRESS_140901] (2%)  
 > 2.[ADDRESS_140902] (<1%)  
o Creatinine (mg/dL)  
 >1.[ADDRESS_140903] or increase of >0.3 mg/dL above baseline (2 -3%) 
 >1.[ADDRESS_140904] or increase of 1.5 x above baseline (2%)  
o Aspar tate aminotransferase (IU/L)  
 2.5 - <5.[ADDRESS_140905] (2 -4%) 
 > [ADDRESS_140906] (<1%)  
o Alanine aminotransferase (IU/L)  
 2.5 - <5.[ADDRESS_140907] (3%)  
 > [ADDRESS_140908] (<1 -1%) 
o Alkaline phosphatase (IU/L)  
 2.5 - <5.[ADDRESS_140909] (<1%)  
o Lipase  
 1.5 - <3.[ADDRESS_140910] (4 -5%) 
 > [ADDRESS_140911] (1 -3%) 
o Creatine Kinase (IU/L)  
 6 - <[ADDRESS_140912] 2%)  
 >[ADDRESS_140913] (2 -3%) 
o Cholesterol, fasted (mg/dL)  
 >300 mg/dL (<1%)  
o LDL Cholesterol, fasted (mg/dL)  
 >190 mg/dL (<1%)  
o Triglycerides, fasted (mg/dL)  
 >500 mg/dL (<1%)  
7.[ADDRESS_140914] common adverse events (for All Grades) have been reported ( > 5%) with the 
chronic use of lamivudine in patients with HIV infection. The reported adverse event rates 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ADDRESS_140915] been reported in patients, it may be 
possible that healthy volunteers may also experience these side effects under this protocol.   
 Body as a Whole  
o Headache (35%)  
o Malaise & fatigue (27%)  
o Fever or chills (10%)  
 Digestive  
o Nausea (33%)  
o Diarrhea (18%)  
o Nausea & vomiting (13%)  
o Anorexia and/or decreased appetite (10%)  
o Abdominal pain (9%)  
o Abdominal cramps (6%)  
o Dyspepsia (4% ) 
o Flatulence (4%)  
 Nervous System  
o Peripheral neuropathy  (5%) 
o Insomnia (4%) 
o Dizziness (3 %) 
o Depressive disorders (8 %) 
 Respi[INVESTIGATOR_696]  
o Pneumonia (3%)  
 Skin  
o rashes (9%)  
 Musculoskeletal  
o Musculoskeletal pain (12%)  
o Myalgia (8%)  
o Arthralgia (5%)  
 Laboratory abnormalities  
o Absolute neutrophil count (<750/mm3) (15%)  
Less co mmonly reported ( < 2%) with chronic use of lamivudine in patients with HIV on 
concomitant ARVs include:  
 Laboratory abnormalities  
o Hemoglobin (<8 g/L) (2.2 %) 
o Platelets (<50,000/mm3) (2.8%) 
o ALT (>5.[ADDRESS_140916]) (3.8%)  
o AST (>5.[ADDRESS_140917]) (4.0%)  
o Bilirubin (>2.[ADDRESS_140918]) (0.8%)  
o Amylase (>2.[ADDRESS_140919]) (2.2%)  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ADDRESS_140920] common adverse events (for All Grades) have been reported ( > 3%) with the 
chronic use of tenofovir disoproxil  fumarate in patients with HIV infection. The reported 
adverse event rates reflect chronic daily use together with other ARVs and are derived from 
large clinical trials in patients with HIV. Although these adverse event rates have been reported 
in patients , it may be possible that healthy volunteers may also experience these side effects 
under this protocol.   
 Body as a Whole  
o Headache (8%)  
o Abdominal pain (7%)  
o Back pain (4%)  
o Chest pain (3%)  
o Fever (4%)  
 Digestive  
o Nausea ( 11%) 
o Diarrhea (16 %) 
o Vomiting (7 %) 
o Dyspe psia (5)  
 Nervous System  
o Neuropathy (12%)  
o Insomnia & other sleep disorders (11%)  
o Dizziness (10%)  
o Depressive disorders (9%)  
 Respi[INVESTIGATOR_696]  
o Nasal signs & symptoms (20%)  
o Cough (18%)  
 Skin  
o Rash (7 %) 
o Sweating (3%)  
 Musculoskeletal  
o Myalgia (4%)  
 Metabolic  
o Weight loss (4%)  
 Laboratory abnormalities  
o Triglycerides (>750 mg/dL) (11%)  
o Creatine kinase (M: >990 U/L; F: >845 U/L) (12%)  
o Serum amylase (>175 U/L) (7%)  
o Glycosuria ( >3+) (3%)  
o AST (M: >180 U/L; F: >170 U/L) (4%)  
o ALT (M: >215 U/L; F: >170 U/L) (4%)  
o Serum glucose ( >250 U/L) (3%)  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 35 of 47 
 Less commonly reported ( < 2%) with chronic use of tenofovir disoproxil fumarate in patients 
with HIV on concomitant ARVs include:  
 Laboratory abnormalities  
o Neutrophils (<750/mm3) (2%)  
10 SAFETY, ADVERSE EVENTS (AE) & SERIOUS ADVERSE EVENTS ( SAE)  
10.1 Definitions  
The definitions of an AE or SAE, as well as the method of recording, evaluating, and assessing 
causality of AE and SAE and the procedures for completing and transmitting AE, SAE, and other 
reportable safety event reports can be found in Appendix 2. Adverse  events, SAEs, and other 
reportable safety events will be reported by [CONTACT_2299] (or, when appropriate, by a 
caregiver, surrogate, or the participant's legally authorized representative).  
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AEs, SAEs, and other reporta ble safety events 
for outcome.  
The investigator,  who is a qualified physician, will assess events that meet the definition of an 
AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality.  
10.1.1 Adverse Event (AE)  
An adverse event is defined as any  untoward medical occurrence in a Participant  administered 
an investigational product that occurs during the conduct of a clinical trial and does not 
necessarily have a causal relationship with the study drug(s). This can be any unfavorable and 
unintended physical sign, symptom, laboratory parameter or disease entity that develops or 
worsens in severity during the course of the trial whether considered related to study drug or 
not. Adverse events can include any of the following:  
 
 All suspected adverse med ication reactions. This includes events possibly related to any 
concomitant medication use  
 Physical Injuries or accidents. If a medical condition is known to have caused the injury 
or accident (e.g., a fall secondary to dizziness), the medical condition (d izziness) and the 
accident (fall) will be reported as two separate adverse events.  
 Abnormalities in physiological testing or physical examination (findings that require 
clinical intervention or further investigation beyond ordering a repeat [confirmatory] 
test).  
 Drug interactions  
 Onset or worsening of preexisting clinical illness  
 Laboratory or diagnostic test abnormality that require clinical intervention or further 
investigation (beyond ordering a repeat [confirmatory] test) unless they are associated 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 36 of 47 
 with  an already reported clinical event. A clinical laboratory abnormality should be 
documented as an adverse event if any one of the following conditions is met:  
• The laboratory abnormality is not otherwise refuted by a repeat test to confirm 
the abnormality  
• The abnormality suggests a disease and/or organ toxicity  
• The abnormality is of a degree that requires active management; e.g. more 
frequent follow -up assessments, further diagnostic investigation, etc.  
Diagnostic and therapeutic non -invasive and invasive procedures, such as surgery, should not 
be reported as adverse events. However, the medical condition for which the procedure was 
performed will be reported if it meets the definition of an adverse event.  
 
All adverse events will be assessed and recorded f rom the time Participant  is enrolled into the 
study until the post -trial visit. At each contact [CONTACT_125291] , the investigator or study 
personnel must seek information on adverse events by [CONTACT_5147], as appropriate, 
by [CONTACT_5148]. I nformation on all adverse events, including degree of severity and relationship 
to study agent, should be recorded immediately in the source document.  
10.1.2 Serious Adverse Event (SAE)  
An SAE is an event that is not an AE per definition above, resulting i n death, is life threatening, 
requires inpatient hospi[INVESTIGATOR_1081], results in 
persistent or significant disability/incapacity, is a congenital anomaly or any other important 
medial events.  SAEs must be reported u sing the Serious Adverse Event Form. All events that 
meet the definition of a serious adverse event will be reported as serious adverse events, 
regardless of whether they are protocol -specific assessments.  
10.2 Assessing and Recording AEs & SAEs  
All advers e events, whether serious or non -serious, will be reported from the time a signed and 
dated ICF is obtained until completion of the participant 's last study -related procedure, which 
may include contact [CONTACT_20687] -up of safety.  
 
All adverse events, regardl ess of seriousness, severity, or presumed relationship to study 
intervention, must be recorded using medical terminology in the source document and the CRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a common 
etiology ( e.g. cough, runny nose, sneezing, sore throat, and head congestion should be reported 
as "upper respi[INVESTIGATOR_4416]").  
 
Investigators must record in the CRF their opi[INVESTIGATOR_125278]. All measures required for adverse event management must be 
recorded in the source document and reported.  
During the outpatient phase the Participant  will be provided with a "wallet (study) card" and 
instructed to carry this card with them for the duration of the study indicating the following:  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 37 of 47 
  Study number  
 Statement that the Participant  is participating in a clinical study  
 Investigator's na me and [ADDRESS_140921] telephone number  
 Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_140922] telephone number (for medical staff only)  
10.3 Data Safety Monitoring Plan  
The investigators will oversee the safety of the study. This safety monitoring will include careful  
assessment and appropriate reporting of adverse events as noted above. Independent medical 
monitoring will include a regular assessment of the number and type of serious adverse events. 
A Medical Monitor will be assigned to this study. This will be a phys ician who is not directly 
involved in the study and is not currently a principal investigator [INVESTIGATOR_125279].  The role of the Medical Monitor is to review all reportable AEs/SAEs including grading, 
toxicity assignments, non -reportable A Es, protocol violations/deviations, as well as all other 
safety data and activity data. The Medical Monitor may recommend reporting of adverse 
events and relevant safety data, and may also recommend suspension or termination of the 
study to the investigato rs and IRB.  
11 STATISTICAL AND PHARMACOKINETIC METHODS  
11.1 Sample Size Estimation  
Sample size was determined from the published within -Participant  variability in the 
pharmacokinetic parameters, AUC and C max, for estradiol, doravirine, and tenofovir disoproxil 
fumarate (Table 2) . A sample size of 10  (G*Power version [IP_ADDRESS], University of Kiel, [LOCATION_013]) 
was determined to provide 80% power to reject the null hypothesis that the mean ratios for 
estradiol and doravirine /tenofovir disoproxil fumarate (in both directions) will fall below or 
above the no -effect boundaries defined as 80 -125%, respectively. The calculation assumes a 
mean ratio of 1 (no -effect) for the bi -directional interacting drugs with a two -sided significance 
level of 0.05.   
 
No-effect bo undaries were chosen based on the US Food and Drug Administration Guidance on 
Clinical Drug Interaction Studies. The standard deviation of the paired difference was calculated 
assuming independence between referenc e drug (estradiol or doravirine /tenofovir disoproxil 
fumarate) and co -administered drug. For calculation of standard deviations, a standard normal 
distribution was assumed for studies with n>60. A t -distribution was used for studies with n <60. 
 
Table 2.  Published within -Participant  standard deviat ions pharmacokinetic parameters and 
corresponding number of Participant s to reject the null hypothesis with 80% power.   
 
 
Drug  Within -Participant  standard deviation   
Number of 
Participant s  
 
Reference  Cmax AUC  
Doravrine  0.18  0.17  10 20 
Tenofovir disoproxil 
fumarate  0.11  0.09  5 21 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 38 of 47 
 Estradiol  0.26  0.24  10 22 
 
11.2 Pharmacokinetic Analysis  
Plasma concentrations of DOR and TDF will be used  to calculate the PK parameters for each 
Participant  in the presence or absence of estradiol and spi[INVESTIGATOR_8407]. Similarly, plasma 
concentrations of estradiol will be used to calculate the PK parameters for each Participant  in 
the presence or absence of DO R/3TC/TDF.  
 
Analysis will be conducted via a non -compartmental analysis. Parameters of interest include the 
area under the concentration -time point from time zero extrapolated to infinity (AUC 0-inf), AUC 0-
last, maximum concentration (C max), minimum concen tration at 24 hours (surrogate for efficacy), 
time to maximum concentration (T max), apparent oral clearance (CL/F) and the apparent half -
life (t 1/2) for each participant . The AUC 0-last will be computed using the linear -up, log -down 
trapezoidal integration method. A log -linear regression using the least -squares method will be 
employed to estimate other parameters of interest including the terminal half -life generated 
from the plasma concentration time -curve.  
The primary endpoint will be pharmacokinetic and therefore be measured as the exposure 
parameters AUC 0-last, Cmax and C trough  
11.3 Statistical Analysis of Pharmacokinetic Parameters  
Estradiol pharmacokinetic parameter estimates computed before and after DOR/3TC/TDF  
dosing will be compared using a paired student’s t -test. Statistical significance will be defined as 
a p-value <0.05. Geometric mean ratio (GMRs) will be estimated for estradiol. An analysis of 
variance model will be performed with 90% confidence interval s around the GMRs between 
reference (estradiol alone) and test (estradiol + DOR/3TC/TDF) will be constructed and 
compared to the no -effect boundaries (0.8, 1.25).  
 
DOR/TDF pharmacokinetic parameter estimates computed before and after estradiol dosing 
will be compared using a paired student’s t -test. Statistical significance will be defined as a p -
value <0.05. Geometric mean ratio (GMRs) will be estimated for DOR/TDF. An analysis of 
variance model will be performed with 90% confidence intervals around the GM Rs between 
reference (DOR/TDF alone) and test (DOR/3TC/TDF + estradiol) will be constructed and 
compared to the no -effect boundaries (0.8, 1.25).  
11.4  Safety Analysis  
Safety and tolerability assessments will be clinically reviewed for any adverse events and 
include safety lab, vital signs, and physical exam beyond the pre -defined limit of change. 
Assessment will be performed for all participants enrolled into this study .  
Safety results will be summarized and tabulated using descriptive statistics. Results will be 
reported as the proportion of Participant s experiencing an adverse event.  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ADDRESS_140923] consent in writing to study participation. The 
Participant  will sign and personally date the patient ICF. The person rendering consent will also 
sign and personally date the ICF as the person who obtained the consent of the Participan t. Each 
Participant  will receive a copy of his or her signed ICF.  
12.3 Participant  Confidentiality  
All records will be kept in a locked filing cabinet located in the offices of the Department of 
Pharmacology and Experimental Therapeutics in 1170 Main Build ing. All computer entry and 
networking programs will be performed with coded numbers only; no PHI will be entered into 
the eCRF. Clinical information will not be released without written permission of the patient, 
except as necessary for monitoring by [CONTACT_7195], IRB, or the FDA, or other medical 
practitioner to ensure the safety and appropriate medical management of th e patient in the 
event of a AE/ SAE.    
  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 40 of 47 
 13 SUPPORTING DOCUMENTATION   
13.1 Appendix 1: Time Windows for Serial Assessments and Dosing  
 
Sampling Window  
Sampling Timepoint (Hours)  Sampling Window (Minutes)  
Pre-dose (DOR/3TC/TDF, estradiol, and 
spi[INVESTIGATOR_8407])  -30 minutes to 0 hour  
  
> 0 hour – 4 hours  -10 minutes to +10 minutes  
> 4 hours – 24 hours  -15 minutes to +1 5 minutes  
> 24 hours – 96 hours  -30 minutes to + 30 minutes  
 
Dosing Window  
Dosing Timepoint  Dosing Window (Minutes)  
DOR/3TC/TDF (Treatment A and Treatment C)  0 hour  
Estradiol and Spi[INVESTIGATOR_8407] (first dose)  0 hour  
Estradiol and Spi[INVESTIGATOR_8407] (second dose)  + 30 minutes from actual 0 hour time . Take this 
within 5 minutes of DOR/3TC/TDF for TX C.  
 
Pre-Dose Assessment Window  
Assessment  Assessment Window (Minutes)  
Physical Exam  -24hours  
Vital Signs  -60 minutes to 0 hour  
CBC/Chemistry  -24 hour s 
Estradiol/Total testosterone ( day 1 pre -dose)  -30 minutes to 0 hour  
Estradiol/Total testosterone( day [ADDRESS_140924] -dose)  Same as DOR /3TC/TDF sampling windows  
 
13.2 Appendix 2: Clinical Laboratory Tests   
 Tests detailed in table 3 will be performed by [CONTACT_125292][INVESTIGATOR_307] – 
Clinical Chemistry Laboratories  
 Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
Table 3:  Protocol required laboratory assessments  
Laboratory 
Assessment  Parameter  
Hematology   Platelet count  
 Hemoglobin  
 Hematocrit  
 WBC with differential  
 Partial thromboplastin time  
 Prothrombin time  
Chemistry   Albumin  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 41 of 47 
  Calcium  
 Chloride  
 Bicarbonate  
 Phosphorus  
 Potassium  
 Sodium  
 Creatinine  
 Total Bilirubin  
 Direct bilirubin (If total bilirubin is elevated above the upper limit of 
normal)  
 Total protein  
 Blood urea nitrogen  
 Glucose  
 Aspartate Aminotransferase (AST)  
 Alanine aminotransferase (AL T) 
 Alkaline phosphatase  
Urinalysis   Specific gravity  
 Microscopic examination (if blood or protein is abnormal)  
 Blood  
 Glucose  
 Specific gravity  
Other Laboratory 
Tests   Serology (Hepatitis B surface antigen [HBsAg] and hepatitis C virus 
antibody). Hepatitis C viral load may additionally be assessed as 
confirmation for participants with a positive antibody test  
 Human immunodeficiency virus screen  
 Urine drug screen to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and b enzodiazepi[INVESTIGATOR_1651]  
 Blood alcohol level  
 Testosterone level  
 Estradiol level  
 
  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 42 of 47 
 13.3 Appendix 3: Adverse Events: Definitions and procedures for Recording, Evaluating, 
Follow -up and Reporting  
13.3.1 Definition of AE  
 An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the procedural study intervention, whether or not considered related to 
the procedural study intervention  
 An AE can therefore any unfavorable and unintend ed sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated 
with the procedural study intervention  
Events meeting the AE definition   
 Any abnormal laboratory test results (hematology, clinical chemistry , or urinalysis) or 
other safety assessments (eg, ECG, vital signs, or measurements), including those that 
worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the investigator  
 New conditions detected or diagnos ed after conduct of the procedural study 
intervention even though it may have been present before the start of the study  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of a concomitant 
medication  
 For all reports of overdose (whether acci dental or intentional) with an associated AE, 
the AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported 
using the terminology “accidental or int entional overdose without adverse effect.”  
Events NOT meeting the AE definition  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307])  
 Surgery planned prior to informed consent to treat a pre -existing condition that has not 
worsened  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen  
13.3.2 Definition of SAE  
 If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met  
 An SAE is defined as any untoward medical occurrence that:  
o Results in death  
o Is life threatening  
 The term “life -threatening” in the definition of “serious” refers to an 
event in which the partici pant was at risk of death at the time of the 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ADDRESS_140925] 
caused death, if it were more severe  
o Requires inpatient hospi[INVESTIGATOR_1081]  
 Hospi[INVESTIGATOR_125280] d as an inpatient admission, regardless of length 
of stay, even if the hospi[INVESTIGATOR_2138] a precautionary measure for 
continued observation. (Note: Hospi[INVESTIGATOR_125281] a pre -existing condition that has not worsened is not an SAE. A 
pre-existing condition is a clinical condition that is diagnosed prior to 
study intervention and is documented in the participant’s medical 
history.  
o Results in persistent or significant disability/incapacity  
13.3.3 Additional Events Reported  
In addition to the above criteria, AEs meeting either of the below criteria, although not serious 
per ICH definition, are reportable:  
 Is a cancer  
 Is associated with an overdose of medication  
13.3.4 Recording AEs and SAEs  
When an AE/SAE occurs, it is the resp onsibility of the investigator to review all documentation 
(e.g. hospi[INVESTIGATOR_1088], laboratory and diagnostic reports) related to the event. The 
investigator will record all relevant AE/SAE information on the AE CRFs at each examination. 
The investig ator will attempt to establish a diagnosis of the vent based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of intensity/toxicity  
 An eve nt is definied as “serious” when it meets at least 1 of the pre -defined outcomes 
as described in the definition of an SAE, not when it is rated as severe  
 The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safet y event) reported during the study and assign it to 1 of the following 
categories:  
o Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort, and not interfering with everyday activities  
o Moderate:  An event that causes suffici ent discomfort to interfere with normal 
everyday activities  
o Severe:  An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category used for 
rating the intensity of an event; and  both AE and SAE can be assessed as severe  
 
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 44 of 47 
 Assessment of causality  
The determination of the likelihood that the study intervention caused the AE will be provided 
by [CONTACT_19427] a qualified physician. The investigator’s signed/dated initials on  the 
source document that supports the causality noted on the AE form, ensures that medically 
qualified assessment of causality was done. This initialed document must be retained for the 
required regulatory time frame. The criteria below are intended as re ference guidelines to 
assist the investigator in assessing the likelihood of a relationship between the study 
intervention and the AE based upon the available information.  
The following components are to be used to assess the relationship between the stud y 
intervention and the AE:  
 Time Course: Did the AE follow in a reasonable temporal sequence from the study 
intervention?  
 Likely Cause:  Is the AE not reasonably explained by [CONTACT_121283], other drug(s)/vaccine(s), or other ho st or environmental factors.  
 Consistency with study intervention:  Is the clinical/pathological presentation of the AE 
consistent with previous knowledge regarding the procedural study intervention?  
The assessment of relationship will be reported on the cas e report forms/worksheets by [CONTACT_26368] a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements. Use the following scale of criteria as guidance (not all 
criteria must be present to be in dicative of a procedural study intervention relationship).  
 Yes, there is a reasonable possibility of study intervention relationship:  
o The temporal sequence of the AE onset relative to the study intervention is 
reasonable. The AE is more likely explained by  [CONTACT_125293]  
 No, there is not a reasonable possibility of procedural study intervention relationship:  
o Temporal sequence of the AE onset relative to study intervention is not 
reasonable OR the AE is more likely explained by [CONTACT_125294]/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may include 
additional laboratory tests or investigations, histopathological examinations, or consultation 
with other health care professionals.  
13.[ADDRESS_140926]  
Case Report Forms  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 45 of 47 
 Source Documents  
Data Management and Clinical Monitoring Plan  
Pharmacy Repackaging Manual    
  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 46 of 47 
 14 REFERENCES  
 
1. Clark H, Babu AS, Wiewel EW, Opoku J, Cre paz N. Diagnosed HIV Infection in 
Transgender Adults and Adolescents: Results from the National HIV Surveillance System, 
2009 -2014. AIDS Behav. 2017;21(9):2774 -2783.  
2. Hembree WC, Cohen -Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender -
Dysphoric /Gender -Incongruent Persons: An Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab. 2017;102(11):3869 -3903.  
3. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of 
HIV in transgender women: a systematic review and meta -analysis. Lancet Infect Dis. 
2013;13(3):[ADDRESS_140927] CL, Mullins MM, Higa DH, Sipe TA. Estimating the Prevalence of HIV 
and Sexual Behaviors Among the US Transgender Population: A Systematic Review and 
Meta -Analysis, 2006 -2017. Am J Public Health. 2018:e1 -e8. 
5. Operario D, Soma T, Underhill K. Sex work and HIV status among transgender women: 
systematic review and meta -analysis. J Acquir Immune Defic Syndr. 2008;48(1):97 -103.  
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of 
Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health 
and Human Services. Available at 
http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf . Section 
accessed [February 25, 2019].  
7. Braun HM, Candelario J, Hanlon CL, et al. Transgender Women Living with HIV 
Frequently Take Anti retroviral Therapy and/or Feminizing Hormone Therapy Differently 
Than Prescribed Due to Drug -Drug Interaction Concerns. LGBT Health. 2017;4(5):371 -
375.  
8. Gogia S, Coromilas A, Regan S, et al. Cardiovascular Risk Profile of Transgender Women 
With HIV: A US  Health Care Database Study. J Acquir Immune Defic Syndr. 
2018;79(1):e39 -e41.  
9. Getahun D, Nash R, Flanders WD, et al. Cross -sex Hormones and Acute Cardiovascular 
Events in Transgender Persons: A Cohort Study. Ann Intern Med. 2018;169(4):205 -213.  
10. Nota  NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M. The 
Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving 
Hormone Therapy: Results from a Large Cohort Study. Circulation. 2019.  
11. Koh KH, Jurkovic S, Yang K, et al. Estradiol induces cytochrome P450 2B6 expression at 
high concentrations: implication in estrogen -mediated gene regulation in pregnancy. 
Biochem Pharmacol. 2012;84(1):93 -103.  
12. Higashi E, Fukami T, Itoh M, et al. Human CYP2A6 is induced by [CONTACT_125295]. Drug Metab Dispos. 2007;35(10):1935 -1941.  
13. Chen H, Yang K, Choi S, Fischer JH, Jeong H. Up -regulation of UDP -
glucuronosyltransferase (UGT) 1A4 by 17beta -estradiol: a potential mechanism of 
increased lamotrigine elimination in pre gnancy. Drug Metab Dispos. 2009;37(9):1841 -
1847.  
Investigating Drug interactions between antiretrovirals and feminizing hormones (IDentify)  
Protocol Version: 1.1  
Protocol Date: 14 February 2020          
JeffTrial Number: [ZIP_CODE]  
Page 47 of 47 
 14. Tocchetti GN, Arias A, Arana MR, et al. Acute regulation of multidrug resistance -
associated protein 2 localization and activity by [CONTACT_125296] -17beta -D-
glucuronide in rat intestine and Caco -2 cell s. Arch Toxicol. 2018;92(2):[ADDRESS_140928] Pharmaco l. 1994;127(2):[ADDRESS_140929] of pregnane X receptor (PXR) prototype agonists on 
chemoprotective and drug metabolizing enzymes in mice. Eur J Pharmacol. 2011;660(2 -
3):[ADDRESS_140930] transcription pathways. 
Toxicol Sci. 2002;67(2):182 -189.  
18. Hiransuthikul A et al. Drug -drug interaction s between the use of feminizing hormone 
therapy and pre -exposure prophylaxis among transgender women: the iFACT study. 
22nd International AIDS Conference (AIDS 2018), Amsterdam, abstract TUPDX0107LB, 
2018.  
19. Center of Excellence for Transgender Health, D epartment of Family and Community 
Medicine, University of [LOCATION_004] San Francisco. Guidelines for the Primary and Gender -
Affirming Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, 
ed. June 2016. Available at www.transhealth.ucsf.edu/  guidelines.  
20. Yee KL, Sanchez RI, Auger P, et al. Evaluation of Doravirine Pharmacokinetics When 
Switching from Efavirenz to Doravirine in Healthy Subjects. Antimicrob Age nts 
Chemother. 2017;61(2).  
21. He C, Griffies A, Liu X, Adamczyk R, Huang SP. A Pooled Analysis of Pharmacokinetic 
Variability Information for Common Probe Substrates Used in Drug -Drug Interaction 
Studies. Pharmacology. 2018;101(3 -4):170 -175.  
22. Harrison LL, Harari D. An evaluation of bioequivalence of two 7 -day 17beta -estradiol 
transdermal delivery systems by [CONTACT_125297]. J Clin Pharmacol. 2002;42(10):1134 -
1141.  
 